The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
December 2003
in “The New England Journal of Medicine”
TLDR Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
The study investigated the long-term effects of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia (BPH). The study involved 3047 men and lasted for 4.5 years. The results showed that doxazosin and finasteride significantly reduced the risk of overall clinical progression, while combination therapy was more effective than either drug alone. Combination therapy and finasteride alone also reduced the long-term risk of acute urinary retention and the need for invasive therapy. The study concluded that long-term combination therapy with doxazosin and finasteride was safe and effective in reducing the risk of overall clinical progression of benign prostatic hyperplasia.
View this study on nejm.org →
Cited in this study
research Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
research The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Finasteride effectively treats BPH but may increase sexual dysfunction risk.
Related
research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.